Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 3/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | CPT1A | P50416 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27649014 | 0.85 | POLB (0.41) | GRM5CPT1A | |
| SCHEMBL5478186 | 0.85 | HCRTR1 (0.39) | HCRTR1HCRTR2CYP3A4GRM5CPT1A | |
| SCHEMBL5478774 | 0.83 | GRM5 (0.38) | HCRTR1HCRTR2CYP3A4GRM5 | |
| SCHEMBL5478779 | 0.83 | GRM5 (0.38) | HCRTR1HCRTR2CYP3A4GRM5 | |
| SCHEMBL5482416 | 0.83 | CPT1A (0.58) | CPT1A | |
| SCHEMBL5784886 | 0.78 | POLB (0.37) | GRM5 | |
| SCHEMBL5489081 | 0.73 | GRM5 (0.38) | CYP3A4GRM5 | |
| SCHEMBL8238657 | 0.72 | GRM5 (0.52) | GRM5CPT1A | |
| SCHEMBL5304397 | 0.72 | CPT1A (0.53) | GRM5CPT1A | |
| SCHEMBL5475092 | 0.72 | GRM5 (0.42) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185100-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| EP-1716143-A1 | POLYHETEROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2006-11-02 | — | — | EP | disclosed |
| US-20060025414-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2006-02-02 | — | — | US | disclosed |
| WO-2005080386-A1 | POLYHETEROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025414-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM3, GRM1, GRM4 | HCRTR1 109/4885HCRTR2 140/4885CYP3A4 1885/4885 |
| US-20070185100-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM3, GRM1, GRM4 | HCRTR1 113/4885HCRTR2 143/4885CYP3A4 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.